1. A patient receives a large cumulative dose of succinylcholine via repeated boluses over 45 minutes. The anesthesiologist notes that the train-of-four (TOF) stimulation pattern — a test in which four electrical stimuli are applied to a peripheral nerve at 2 Hz and the resulting muscle twitches are counted and compared — has changed character: the initial fade pattern has disappeared and been replaced by a non-fade response that now resembles non-depolarizing block. Administration of neostigmine at this point paradoxically deepens rather than reverses the block. Which of the following correctly identifies this phenomenon and explains the TOF behavior?

• A) This represents tachyphylaxis to succinylcholine — repeated dosing has saturated all available end-plate receptors, and the absence of fade reflects complete receptor occupancy with no residual receptor reserve for neostigmine to act upon.
• B) This represents desensitization block — succinylcholine has caused irreversible conformational changes in the nAChR that lock the channel in a permanently closed state, producing a block that is clinically indistinguishable from competitive antagonism and that resolves only after receptor turnover over 48 to 72 hours.
• C) This represents Phase II (dual) block — prolonged or high cumulative succinylcholine exposure causes the end plate to transition from the initial depolarization-dependent Phase I block to a Phase II state that exhibits fade on TOF stimulation and is paradoxically worsened by neostigmine, which inhibits residual pseudocholinesterase and prolongs succinylcholine exposure at the receptor.
• D) This represents competitive displacement of succinylcholine by accumulating succinylmonocholine — the primary metabolite of succinylcholine hydrolysis — which acts as a partial agonist at the nAChR and produces a mixed agonist-antagonist pattern that mimics non-depolarizing block on TOF monitoring.
• E) This represents neuromuscular fatigue from repetitive end-plate depolarization — the muscle fiber contractile apparatus becomes exhausted by sustained activation, and the TOF fade pattern reflects failure of the excitation-contraction coupling mechanism rather than any change in receptor pharmacology.

2. A 7-year-old boy receives succinylcholine 2 mg/kg intravenously for emergency intubation. Within 60 seconds of injection, his heart rate drops from 102 to 48 beats per minute. A second dose is administered 8 minutes later and the bradycardia recurs, this time more pronounced. Which of the following correctly explains the mechanism and clinical pattern of this adverse effect?

• A) Succinylcholine stimulates cardiac muscarinic (M2) receptors — either directly or via its metabolite succinylmonocholine — producing parasympathomimetic slowing of sinus node discharge; this effect is most pronounced in children (who have higher baseline vagal tone than adults) and is characteristically more severe with a second dose, making prophylactic atropine standard practice in pediatric succinylcholine protocols.
• B) Succinylcholine activates nicotinic receptors in the cardiac conduction system, producing a reflex bradycardia through a direct negative chronotropic effect on the sinoatrial node that is dose-proportional and equally pronounced in adults and children at equivalent mg/kg doses.
• C) The bradycardia represents a baroreceptor reflex response to the transient blood pressure surge caused by succinylcholine-induced fasciculations — the intense simultaneous muscle contraction raises intrathoracic pressure, reduces venous return, and activates vagal afferents; the effect is more pronounced in children because of their smaller thoracic volume relative to muscle mass.
• D) Succinylcholine inhibits the cardiac sodium-potassium ATPase, causing potassium accumulation in the myocardium that depolarizes conduction tissue and slows the ventricular rate; this effect is amplified in children because their sodium-potassium ATPase has lower baseline inhibitor resistance than in adults.
• E) The bradycardia is a histamine-mediated effect — succinylcholine releases histamine from cardiac mast cells, and H1 receptor activation on atrial tissue directly reduces automaticity; this mechanism explains why the second dose produces more bradycardia, as histamine stores are partially depleted and the receptor becomes upregulated after the first exposure.

3. Two patients on the same ICU ward both require emergency intubation. Patient A suffered an ischemic stroke 10 hours ago and has right-sided hemiplegia. Patient B suffered an ischemic stroke 3 weeks ago and has persistent left-sided hemiplegia with significant muscle wasting. The team asks whether succinylcholine can be safely used in each patient. Which of the following correctly stratifies the hyperkalemia risk from succinylcholine between these two patients?

• A) Both patients carry equivalent high risk of succinylcholine-induced life-threatening hyperkalemia because ischemic stroke immediately triggers systemic upregulation of extrajunctional nAChRs across all skeletal muscle groups within hours of the neurological event.
• B) Patient A carries higher risk than Patient B because the acute phase of stroke is associated with maximal systemic inflammatory cytokine release, which peaks at 6 to 24 hours after onset and transiently sensitizes nAChRs to succinylcholine-induced potassium efflux before subsiding.
• C) Neither patient carries meaningful additional risk compared to a neurologically intact patient, because succinylcholine-induced hyperkalemia in stroke requires bilateral motor neuron lesions; a unilateral hemispheric stroke preserves the contralateral corticospinal tract and sufficient intact neuromuscular signaling to prevent extrajunctional receptor upregulation.
• D) Both patients carry equivalent risk, but the risk is clinically insignificant in either case because the upregulated extrajunctional receptors in denervated muscle are structurally different from junctional receptors and have lower single-channel conductance, limiting the total potassium efflux to a clinically trivial amount regardless of the total number of channels activated.
• E) Patient A carries substantially lower risk than Patient B — extrajunctional nAChR upregulation requires time to develop after denervation and is not yet established within the first 24 hours of a neurological injury, so succinylcholine given at 10 hours post-stroke carries little additional hyperkalemia risk; by contrast, after 3 weeks of hemiplegia with muscle wasting, extrajunctional receptors are well established across the denervated muscle surface and succinylcholine poses a genuine risk of life-threatening hyperkalemia.

4. A patient emerges from anesthesia 28 minutes after receiving succinylcholine 1.2 mg/kg for intubation — still requiring ventilatory support but with spontaneous respiratory effort beginning. A dibucaine number drawn from the preoperative sample returns at 62. Which of the following best explains the clinical course and predicts the patient's recovery trajectory?

• A) A dibucaine number of 62 indicates near-normal pseudocholinesterase function — values between 60 and 70 fall within the normal range of assay variability, and the prolonged block is most likely explained by a drug interaction reducing hepatic blood flow rather than by enzyme deficiency.
• B) A dibucaine number of approximately 60 indicates the heterozygous pseudocholinesterase phenotype — one normal and one atypical gene — producing an enzyme population with intermediate dibucaine inhibition; this genotype typically extends succinylcholine block to 20 to 30 minutes rather than the normal 8 to 12, which is consistent with this patient's course; full spontaneous recovery is expected within the next 15 to 30 minutes without pharmacological intervention.
• C) A dibucaine number of 62 indicates the homozygous atypical pseudocholinesterase phenotype, which has a characteristic dibucaine number range of 55 to 65; this patient should be expected to remain apneic for 3 to 6 hours and will require prolonged ICU ventilation before spontaneous recovery.
• D) A dibucaine number of 62 confirms pseudocholinesterase deficiency but also indicates that the patient will respond normally to neostigmine reversal, because dibucaine numbers above 50 preserve sufficient acetylcholinesterase inhibition for anticholinesterase reversal to accelerate recovery.
• E) A dibucaine number of 62 identifies this patient as being at elevated risk for malignant hyperthermia on future anesthetic exposure — the intermediate dibucaine number reflects heterozygous RYR1 mutation carriage, and the prolonged block occurred because the succinylcholine triggered partial calcium dysregulation that impaired the muscle's ability to generate the contractile response needed for respiratory recovery.

5. Rocuronium and vecuronium are both intermediate-duration aminosteroid non-depolarizing agents with similar mechanisms of action and elimination pathways, yet rocuronium achieves intubating conditions approximately 30 seconds faster than vecuronium at equipotent doses. Which of the following correctly explains the pharmacokinetic property responsible for rocuronium's faster onset?

• A) Rocuronium has a higher receptor binding affinity (lower ED95) than vecuronium, meaning that a smaller fraction of neuromuscular junction receptors must be occupied to produce complete block — this lower occupancy threshold is reached more rapidly at the concentration that first arrives at the NMJ.
• B) Rocuronium undergoes less first-pass hepatic extraction than vecuronium after intravenous injection, resulting in a higher initial plasma concentration that drives a steeper concentration gradient toward the NMJ biophase and produces faster onset of receptor occupancy.
• C) Rocuronium is eliminated more slowly than vecuronium — its longer half-life maintains higher plasma concentrations during the distribution phase, sustaining the driving concentration gradient toward the NMJ for longer and accelerating the rate of receptor occupancy.
• D) Rocuronium is more lipophilic than vecuronium — greater lipophilicity facilitates faster diffusion across the lipid-rich tissue barriers between the plasma compartment and the neuromuscular junction biophase, reducing the time from injection to effective receptor occupancy at the end plate and accounting for its faster onset despite similar receptor affinity.
• E) Rocuronium is formulated at a higher concentration per milliliter than vecuronium, allowing a larger absolute number of molecules to be delivered in the standard clinical injection volume; the higher molecular density at the injection site accelerates the rate of drug arrival at the NMJ.

6. Vecuronium was developed as a modification of pancuronium specifically to eliminate an unwanted cardiovascular side effect while preserving neuromuscular blocking potency. Which of the following correctly identifies the structural change made and the cardiovascular property that was eliminated?

• A) Vecuronium is the monoquaternary analog of pancuronium, achieved by removing one methyl group from the nitrogen in ring A of the steroidal scaffold; this single structural change eliminates the vagolytic (muscarinic blocking) effect and the sympathomimetic catecholamine reuptake inhibition that make pancuronium produce tachycardia and mild hypertension, giving vecuronium a cardiovascular-neutral profile.
• B) Vecuronium is a reduced-potency analog of pancuronium achieved by replacing one of the two acetoxy groups on the steroidal scaffold with a hydroxyl group, reducing receptor binding affinity and thereby lowering the dose required to produce block; the cardiovascular neutrality of vecuronium results from this lower effective receptor occupancy rather than from any structural change affecting muscarinic receptor binding.
• C) Vecuronium differs from pancuronium by the addition of a piperidinium ring to the steroidal scaffold, which sterically blocks the drug's interaction with cardiac muscarinic receptors while preserving its affinity for the nicotinic receptor at the neuromuscular junction; the net result is selective nicotinic blockade without any muscarinic activity.
• D) Vecuronium is a bisquaternary aminosteroid like pancuronium but has two permanent positive charges positioned closer together on the molecule, reducing the distance between them below the critical threshold for dual nicotinic-muscarinic receptor binding; this geometric change confers NMJ selectivity while eliminating the vagolytic cardiac effect.
• E) Vecuronium is synthesized by substituting the two quaternary nitrogen groups of pancuronium with tertiary nitrogen groups, allowing the drug to cross the blood-brain barrier and access central muscarinic receptors where its pre-synaptic activity counteracts the peripheral vagolytic effect, producing net cardiovascular neutrality through opposing central and peripheral muscarinic actions.

7. Both atracurium and cisatracurium undergo Hofmann elimination producing laudanosine as a degradation product. An ICU team caring for a patient receiving a prolonged infusion asks why cisatracurium is preferred over atracurium for long-term paralysis when both drugs share the same elimination pathway and produce the same metabolite. Which of the following correctly explains cisatracurium's advantage regarding laudanosine accumulation?

• A) Cisatracurium undergoes Hofmann elimination at a slower rate than atracurium, producing laudanosine more gradually over time; the lower rate of metabolite generation keeps peak plasma laudanosine concentrations below the threshold for CNS excitation even during prolonged infusions at the same mg/kg/hour dose.
• B) Cisatracurium produces a structurally distinct isomer of laudanosine that lacks the CNS-excitatory activity of the laudanosine produced by atracurium Hofmann degradation; the different stereochemical configuration of cisatracurium-derived laudanosine prevents it from crossing the blood-brain barrier at concentrations achieved during clinical infusions.
• C) Cisatracurium is approximately three times more potent than atracurium at the neuromuscular junction, so the infusion dose required to maintain equivalent depth of block is proportionally lower; because less total drug mass is administered per hour, less Hofmann degradation occurs per unit time and substantially less laudanosine is generated — the advantage is pharmacokinetic (lower dose needed), not a difference in the Hofmann pathway itself.
• D) Cisatracurium contains only a single stereoisomer that is preferentially metabolized by plasma esterase hydrolysis rather than Hofmann elimination, diverting the majority of its metabolism away from the laudanosine-producing pathway and toward a renal excretion pathway that does not generate CNS-active metabolites.
• E) Cisatracurium has a longer context-sensitive half-time than atracurium during prolonged infusion, meaning that when the infusion is stopped the plasma concentration declines more slowly; this slower decline paradoxically produces lower peak laudanosine concentrations because the drug degrades to laudanosine more evenly over a longer post-infusion period rather than in a rapid burst.

8. At the end of a laparoscopic procedure, the anesthesiologist quantitatively monitors neuromuscular recovery using train-of-four (TOF) stimulation. The patient received rocuronium 0.6 mg/kg at induction. The current TOF count is 2 with fade. The surgeon then unexpectedly requests 20 more minutes of deep relaxation, at which point the TOF count is 0 with a post-tetanic count (PTC) of 1 — indicating profound block. At closure, the anesthesiologist plans to use sugammadex. Which of the following correctly matches the sugammadex dose to the depth of block at each decision point?

• A) At TOF count 2 with fade: sugammadex 16 mg/kg is required because fade indicates deep block; at PTC of 1 (profound block): sugammadex 4 mg/kg is sufficient because the post-tetanic response indicates incomplete receptor occupancy that can be overcome with a moderate encapsulation dose.
• B) At TOF count 2 with fade: sugammadex 2 mg/kg is the standard dose; at PTC of 1: sugammadex 4 mg/kg is required because the complete absence of TOF response with low post-tetanic count identifies this as deep block requiring a higher encapsulation dose.
• C) Sugammadex dose is independent of block depth for rocuronium — because the cyclodextrin encapsulation mechanism creates a fixed stoichiometric ratio regardless of the number of receptor-bound drug molecules present, a standard dose of 4 mg/kg reverses any depth of rocuronium block within the same time frame.
• D) At TOF count 2 with fade: neostigmine is the appropriate reversal agent because sugammadex is not indicated when TOF responses are present and the block is not profound; at PTC of 1: sugammadex 16 mg/kg is required for immediate reversal of profound block.
• E) At TOF count 2 with fade (moderate block): sugammadex 2 mg/kg is the appropriate dose; at TOF count 0 with PTC of 1 (profound block): sugammadex 16 mg/kg is required for reliable reversal; a dose of 4 mg/kg is used for deep block defined as a TOF count of 0 with PTC of 2 or more — the three-tier dosing scheme reflects the need for sufficient sugammadex to encapsulate all circulating rocuronium molecules at each depth of block.

9. Mivacurium is described as the shortest-acting non-depolarizing neuromuscular blocking agent in clinical use, with a normal duration of 12 to 20 minutes. Despite this attractive profile for short procedures, its clinical use is limited by two specific pharmacological liabilities. Which of the following correctly identifies both limiting properties?

• A) Mivacurium's clinical utility is limited by its inability to be reversed by sugammadex at any dose, and by its exclusively renal elimination that makes its duration unpredictably prolonged in patients with even mild renal impairment.
• B) Mivacurium's clinical utility is limited by its dependence on plasma pseudocholinesterase for hydrolysis — making its duration highly variable and potentially dramatically prolonged in patients with pseudocholinesterase deficiency — and by its histamine-releasing tendency at higher doses, which can produce flushing, hypotension, and bronchospasm, particularly if administered rapidly.
• C) Mivacurium's clinical utility is limited by its exclusively hepatic elimination through cytochrome P450 3A4-mediated oxidation, making its duration unpredictably prolonged in patients with hepatic disease or receiving CYP3A4 inhibitors, and by its tendency to produce dose-dependent tachycardia through vagolytic muscarinic receptor blockade.
• D) Mivacurium's clinical utility is limited by its accumulation of a potent active metabolite that blocks nicotinic receptors with higher affinity than the parent compound, and by its direct myocardial depressant effect at doses required for reliable intubating conditions.
• E) Mivacurium's clinical utility is limited by its propensity to trigger malignant hyperthermia in susceptible individuals through a mechanism distinct from succinylcholine — mivacurium activates ryanodine receptors at high doses — and by a prolonged onset time of 4 to 5 minutes at standard doses that limits its utility for procedures requiring rapid intubation.

10. A patient with an eGFR of 18 mL/min receives pancuronium 0.1 mg/kg for a long surgical procedure. Four hours after the last dose, the patient remains deeply paralyzed with a TOF count of zero despite the anticipated clinical duration of 60 to 90 minutes having elapsed more than two hours ago. Which property of pancuronium's elimination is directly responsible for this clinical outcome?

• A) Pancuronium undergoes extensive hepatic glucuronidation in the liver, and severe chronic kidney disease reduces hepatic blood flow by approximately 40%, decreasing the rate of conjugation and extending the drug's half-life in proportion to the reduction in hepatic perfusion.
• B) Pancuronium is primarily eliminated by Hofmann degradation, and the acidosis associated with chronic kidney disease (serum bicarbonate typically 16 to 18 mEq/L in stage 5 CKD) lowers physiological pH below the threshold required for efficient spontaneous molecular degradation, slowing the elimination rate by 60 to 70% compared to normal pH conditions.
• C) Pancuronium accumulates in renal failure because the kidneys are responsible for activating the drug to its active form — the diacetyl precursor compound is renally converted to the active bisquaternary parent molecule — and impaired conversion leaves the inactive precursor circulating at higher concentrations, prolonging the apparent duration of block as slow non-renal conversion continues.
• D) Pancuronium is eliminated approximately 80% unchanged by the kidneys via glomerular filtration and renal tubular secretion; in a patient with an eGFR of 18 mL/min representing severely reduced renal clearance, the rate of pancuronium excretion is markedly diminished, causing the drug to accumulate and producing prolonged block far beyond the expected duration in a renally intact patient.
• E) Pancuronium binds extensively to plasma proteins, and the hypoalbuminemia associated with chronic kidney disease dramatically increases the free drug fraction, raising the concentration of pharmacologically active unbound drug at the neuromuscular junction and producing a deeper and more prolonged block than would be expected from the administered dose in a normally albumin-replete patient.

11. Postoperative residual neuromuscular blockade (RNMB) — defined as a train-of-four ratio below 0.9 at tracheal extubation — is associated with clinically significant morbidity in the postoperative period. Which of the following correctly describes the risk factors for RNMB and its primary clinical consequence?

• A) Long-acting neuromuscular blocking agents are associated with substantially higher rates of RNMB than intermediate-acting agents because their prolonged clinical duration and slow spontaneous recovery make it difficult to guarantee adequate recovery by the end of surgery without pharmacological reversal; a TOF ratio below 0.9 at extubation is associated with impaired pharyngeal muscle function, upper airway obstruction, and an increased risk of pulmonary aspiration and hypoxemic complications in the postoperative period.
• B) RNMB risk is highest with intermediate-acting agents such as rocuronium and vecuronium compared to long-acting agents because intermediate-duration drugs reach their peak plasma concentration later in the case, creating a paradoxical residual effect at extubation that is not present with long-acting agents whose peak effect has already waned by surgical closure.
• C) RNMB is clinically significant only when the TOF ratio falls below 0.6 — values between 0.6 and 0.9 represent subclinical residual block that is hemodynamically and respiratorily inert; the 0.9 threshold described in older studies was derived from awake volunteer experiments that do not translate to the impaired reflexes of a post-anesthetic patient.
• D) RNMB affects primarily the diaphragm and intercostal muscles, with pharyngeal and laryngeal muscles largely spared because their smaller motor unit size and higher acetylcholine receptor density confer resistance to partial neuromuscular block; the predominant clinical consequence is therefore hypercapnic respiratory failure rather than upper airway obstruction or aspiration.
• E) The primary clinical consequence of RNMB is prolonged sedation rather than neuromuscular dysfunction — the impaired central respiratory drive caused by residual volatile anesthetic interacts with partial neuromuscular block to produce a sedation-paralysis synergy that manifests as hypercapnic failure, and the TOF ratio is therefore not a useful independent predictor of postoperative pulmonary complications.

12. Atracurium and cisatracurium share the benzylisoquinolinium class and both undergo Hofmann elimination, yet they are not clinically interchangeable. Which of the following correctly distinguishes their elimination pathways and the clinical implication of that difference?

• A) Atracurium is eliminated exclusively by Hofmann degradation with no ester hydrolysis component, whereas cisatracurium undergoes dual elimination via both Hofmann degradation and extensive plasma pseudocholinesterase hydrolysis; the ester hydrolysis component of cisatracurium produces a distinct metabolite that has anti-inflammatory properties beneficial in acute respiratory distress syndrome (ARDS) management.
• B) Atracurium and cisatracurium have identical elimination pathways in equal proportions, but cisatracurium's higher receptor affinity means less drug is needed, so at equivalent clinical block depth the absolute rates of Hofmann degradation and ester hydrolysis are proportionally lower for cisatracurium, producing less total metabolite including laudanosine.
• C) Atracurium undergoes elimination via two parallel organ-independent pathways — Hofmann degradation and non-specific plasma ester hydrolysis — whereas cisatracurium's elimination is predominantly Hofmann degradation with a minor ester hydrolysis contribution; atracurium therefore generates more laudanosine per milligram of drug administered than cisatracurium, and also releases more histamine at clinical doses, making cisatracurium the preferred agent when both metabolite accumulation and histamine release are concerns.
• D) Cisatracurium undergoes elimination via both Hofmann degradation and active renal tubular secretion, whereas atracurium is eliminated exclusively by Hofmann degradation; the renal component of cisatracurium elimination makes its duration shorter in patients with normal renal function but markedly prolonged in renal failure — paradoxically making cisatracurium the less predictable agent in patients with kidney disease.
• E) Both atracurium and cisatracurium are eliminated exclusively by Hofmann degradation with no ester hydrolysis; the clinical differences between them relate entirely to receptor selectivity — cisatracurium selectively blocks neuromuscular junction nAChRs while atracurium also blocks autonomic ganglionic nAChRs, causing the cardiovascular effects and histamine release seen at higher doses.

13. A 4-year-old boy presents for elective tonsillectomy. He has no known medical history, and the preoperative assessment is unremarkable. The anesthesiologist considers using succinylcholine for intubation but recalls a specific contraindication in routine pediatric cases. Which of the following correctly identifies this contraindication and its mechanism?

• A) Succinylcholine is contraindicated in all patients under 8 years because developing neuromuscular junctions in children have not yet completed myelination of the motor nerve terminal, leaving the end plate susceptible to irreversible block from depolarizing agents that does not occur once myelination is complete.
• B) Succinylcholine is contraindicated in pediatric patients for routine intubation because children have a proportionally higher cardiac output relative to body weight, producing faster drug delivery to the sinoatrial node and a higher incidence of bradycardia at standard mg/kg doses than the labeling supports for routine use in this age group.
• C) Succinylcholine is contraindicated in all pediatric patients for routine intubation because children metabolize succinylcholine primarily via hepatic cytochrome P450 rather than pseudocholinesterase until approximately age 10, producing prolonged block and scoline apnea at standard weight-based doses.
• D) Succinylcholine is routinely contraindicated in pediatric patients because the increased ratio of extrajunctional to junctional nAChRs that is normal in children under the age of 6 produces exaggerated potassium efflux compared to adults at the same dose, making safe dosing ranges impossible to establish in this population.
• E) Succinylcholine is relatively contraindicated for routine pediatric intubation because undiagnosed skeletal muscle myopathies — most importantly Duchenne muscular dystrophy, which is not always clinically apparent at the time of first anesthetic — are a significant cause of succinylcholine-induced cardiac arrest in children; in susceptible patients, succinylcholine triggers rhabdomyolysis and massive hyperkalemia from disruption of the already-fragile dystrophin-deficient sarcolemmal membrane, and because myopathy may be unrecognized at the time of the procedure, the risk-benefit ratio does not support routine succinylcholine use in pediatric elective cases.

14. At the end of a 90-minute abdominal procedure, the patient received vecuronium 0.1 mg/kg at induction and a maintenance dose 45 minutes later. The anesthesiologist plans to use neostigmine for reversal. The current TOF count is 1 with no post-tetanic facilitation. Which of the following correctly describes the limitations of neostigmine in this situation and the appropriate management?

• A) Neostigmine is appropriate at a TOF count of 1 because its acetylcholinesterase inhibition will increase acetylcholine concentration at the end plate sufficiently to competitively displace vecuronium from the nicotinic receptor and restore full neuromuscular function within 5 minutes; no antimuscarinic co-administration is required because neostigmine's peripheral nicotinic selectivity prevents bradycardia.
• B) Neostigmine cannot reliably reverse deep block — it requires a minimum TOF count of 2 (and ideally spontaneous recovery to T2) to have predictable efficacy, because at deeper levels of block the acetylcholine increase it produces is insufficient to overcome the high degree of receptor occupancy by vecuronium; the correct management is to wait for further spontaneous recovery before administering neostigmine, and to co-administer an antimuscarinic agent (glycopyrrolate or atropine) to prevent the bradycardia and hypersalivation caused by increased muscarinic receptor stimulation.
• C) Neostigmine is the appropriate reversal agent at any depth of non-depolarizing block, including TOF count of 0 — the dose should be increased to the maximum of 0.07 mg/kg when TOF count is low, and the additional acetylcholine generated by this higher dose will overcome even profound receptor occupancy; antimuscarinic pretreatment is only required if heart rate is below 60 at the time of administration.
• D) Neostigmine is contraindicated for vecuronium reversal at any depth because vecuronium's monoquaternary structure creates a covalent bond with the nicotinic receptor that cannot be displaced by increasing acetylcholine concentration; sugammadex is the only effective reversal agent for vecuronium and must be used regardless of depth of block.
• E) Neostigmine reversal is appropriate at a TOF count of 1 without antimuscarinic co-administration because the vecuronium-mediated muscarinic blockade at the sinoatrial node provides intrinsic protection against neostigmine-induced bradycardia; the vagolytic effect of residual vecuronium balances the muscarinic stimulation produced by increased synaptic acetylcholine until block is fully reversed.

15. A 78-year-old man with Child-Pugh class B hepatic cirrhosis requires neuromuscular blockade for an elective inguinal hernia repair. The anesthesiologist selects rocuronium 0.6 mg/kg but anticipates that the clinical duration will be significantly longer than the standard 30 to 45 minutes. Which of the following correctly identifies the elimination route responsible for this prolonged duration and explains why both hepatic disease and advanced age independently contribute to the same pharmacokinetic vulnerability?

• A) Rocuronium is eliminated predominantly by renal glomerular filtration as unchanged parent drug, and both hepatic cirrhosis (which reduces renal perfusion through hepatorenal hemodynamics) and advanced age (which reduces GFR by approximately 1 mL/min per year after age 40) independently reduce renal clearance, prolonging rocuronium half-life proportionally to the combined reduction in GFR.
• B) Rocuronium undergoes Hofmann elimination at a rate proportional to hepatic pH buffering capacity; in cirrhosis, reduced hepatic bicarbonate synthesis lowers systemic pH below the threshold for optimal spontaneous molecular degradation, and in elderly patients reduced renal bicarbonate reabsorption produces a similar mild acidosis — both extending rocuronium half-life through the same pH-dependent mechanism.
• C) Rocuronium is highly bound to alpha-1 acid glycoprotein (AAG), and both hepatic cirrhosis (which reduces AAG synthesis) and advanced age (which increases AAG levels and shifts binding equilibrium) alter free rocuronium fraction in opposite directions, producing unpredictable duration in these populations through competing changes in plasma protein binding.
• D) Rocuronium is eliminated primarily by biliary excretion of unchanged drug and hepatic metabolism, with a minor renal contribution; hepatic cirrhosis reduces hepatic blood flow and hepatocellular metabolic capacity, directly impairing rocuronium clearance and prolonging its half-life; advanced age independently prolongs rocuronium duration through age-related reduction in hepatic blood flow and hepatic mass, which reduces first-pass uptake and metabolic clearance even in the absence of overt hepatic disease.
• E) Rocuronium is eliminated by plasma pseudocholinesterase hydrolysis and hepatic esterases; cirrhosis reduces hepatic esterase synthesis, and advanced age reduces circulating pseudocholinesterase activity by approximately 30% per decade after age 60; both reduce the rate of rocuronium hydrolysis, explaining the prolonged block in this clinical scenario.

16. A 29-year-old woman undergoes a 25-minute laparoscopic procedure under general anesthesia. Succinylcholine 1.2 mg/kg was given for intubation. She is discharged home the same day. Twelve hours later she calls the surgical unit reporting diffuse muscle aches across her neck, chest, abdomen, and thighs that she describes as resembling soreness after unaccustomed intense exercise. Which of the following correctly explains the mechanism of this adverse effect and identifies the population at highest risk?

• A) Postoperative myalgia following succinylcholine results from the asynchronous, unsynchronized fasciculations produced at the onset of depolarizing block — different muscle groups contract in an uncoordinated, overlapping sequence rather than simultaneously, generating shear forces and micro-injury within muscle fibers that produce delayed-onset muscle soreness; the effect is most prevalent in ambulatory patients who become mobile within hours of the procedure (as opposed to patients who remain bedridden), in women, and in those who received the drug without prior defasciculating pretreatment.
• B) Postoperative myalgia following succinylcholine is caused by the drug's inhibition of mitochondrial creatine kinase in skeletal muscle, reducing ATP regeneration capacity during the fasciculation period and producing ischemic micro-injury in the most metabolically active muscle groups; the effect is most common in physically fit patients who have higher baseline metabolic demands in their skeletal muscle.
• C) The muscle soreness results from subclinical rhabdomyolysis triggered by the sodium channel blockade component of succinylcholine at higher doses — at 1.2 mg/kg, a fraction of the drug reaches non-junctional sodium channels and produces membrane instability and calcium influx sufficient to cause enzyme release and inflammatory myopathy detectable on creatine kinase assay in all affected patients.
• D) Postoperative myalgia is a histamine-mediated inflammatory response to succinylcholine that occurs in atopic patients — mast cell histamine release at standard doses triggers local inflammatory cytokine production in skeletal muscle, and the diffuse distribution reflects the systemic histamine release pattern; the effect is prevented by prophylactic antihistamine administration before induction.
• E) The muscle soreness is caused by the Phase II (dual) block component of succinylcholine at intubating doses — the 1.2 mg/kg dose reliably produces Phase II block in all patients, and the transition from Phase I to Phase II block involves a calcium-mediated contracture of the myofilaments that produces micro-tears in the sarcomere; the effect resolves only when the Phase II block fully reverses, typically over 24 to 48 hours.